Given the key role for both FAK and CXCR4 in breast cancer metastasis, FAK- and CXCR4-targeted therapies have been explored in pre-clinical tests and clinical trials [34, 48, 66–69]. The gene discussed is PTK2; the disease is breast carcinoma.